Advertisement

Urinary excretion of salsolinol enantiomers and 1,2-dehydrosalsolinol in patients with degenerative dementia

  • P. Dostert
  • M. Strolin Benedetti
  • V. Bellotti
  • G. Dordain
  • D. Vernay
  • D. Deffond
Part of the Key Topics in Brain Research book series (KEYTOPICS)

Summary

The daily urinary excretion of total (R)- and (S)-salsolinol and 1,2-dehydrosalsolinol (free + sulfoconjugate) was measured in patients with degenerative dementia. (R)-Salsolinol was detectable in the urine of 5 out of 12 patients and 1,2-dehydrosalsolinol in the urine of 10 patients, whereas (S)-salsolinol was not detectable. The urinary excretion of 1,2-dehydrosalsolinol appears to be similar in demented and parkinsonian patients, suggesting that the biosynthesis of salsolinol precursors may be similar in the two groups.

Keywords

Urinary Excretion Parkinsonian Patient Demented Patient Phenylboronic Acid Daily Excretion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Collins MA, Nijm WP, Borge GF, Teas G, Golfarb C (1979) Dopamine-related tetrahydroisoquinolines: significant urinary excretion by alcoholics after alcohol consumption. Science 206: 1184–1186PubMedCrossRefGoogle Scholar
  2. Dordain G, Dostert P, Strolin Benedetti M, Rovei V (1984) Tetrahydroisoquinoline derivatives and Parkinsonism. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, London, pp 417–426Google Scholar
  3. Dostert P, Strolin Benedetti M, Dedieu M (1987) Ratio of enantiomers of salsolinol in human urine. Pharmacol Toxicol 60 [Suppl 1]: 13Google Scholar
  4. Dostert P, Strolin Benedetti M, Dordain G (1988) Dopamine-derived alkaloids in alcoholism and in Parkinson’s and Huntington’s diseases. J Neural Transm 74: 61–74PubMedCrossRefGoogle Scholar
  5. Dostert P, Strolin Benedetti M, Dordain G, Vernay D (1989) Enantiometric composition of urinary salsolinol in Parkinsonian patients after Madopar. J Neural Transm (P-D Sect) 1: 269–278CrossRefGoogle Scholar
  6. Reinikainen KJ, Paljärvi L, Halonen T, Malminen O, Kosma V-M, Laakso M, Riekkinen PJ (1988) Dopaminergic system and monoamine oxidase-B activity in Alzheimer’s disease. Neurobiol Aging 9: 245–252PubMedCrossRefGoogle Scholar
  7. Reisberg B, Ferris SM, De Leon MJ, Crook T (1982) The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 139: 1136–1139PubMedGoogle Scholar
  8. Sandler M, Bonham Carter S, Hunter KR, Stern GM (1973) Tetrahydroisoquino- line alkaloids: in vivo metabolites of L-dopa in man. Nature 241: 439–443PubMedCrossRefGoogle Scholar
  9. Sjöquist B, Borg S, Kvande H (1981) Salsolinol and methylated salsolinol in urine and cerebrospinal fluid from healthy volunteers. Subst Alcohol Actions Misuse 2: 73–77PubMedGoogle Scholar
  10. Sjöquist B, Eriksson A, Windblad B (1982) Salsolinol and catecholamines in human brain and their relation to alcoholism. Prog Clin Biol Res 90: 57–67PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 1990

Authors and Affiliations

  • P. Dostert
    • 1
  • M. Strolin Benedetti
    • 1
  • V. Bellotti
    • 1
  • G. Dordain
    • 2
  • D. Vernay
    • 2
  • D. Deffond
    • 2
  1. 1.Research and Development-Erbamont GroupFarmitalia Carlo ErbaMilanItaly
  2. 2.Hôpital NordService de NeurologieClermont-FerrandFrance

Personalised recommendations